110 likes | 217 Vues
In the 21st century, financing vaccines presents critical challenges at both macro and micro system levels. Nationally, issues such as fragmented public-private financing, financial barriers, and the fragility of vaccine supply hinder equitable access. Declining incentives for manufacturers exacerbate these problems. At the micro level, practices face quality concerns and an increasing number of recommended vaccines, which complicate implementation. This discussion focuses on AAP principles for improving vaccination financing and ensuring that barriers to access and quality are effectively addressed.
E N D